Document is current
Any future updates will be listed below
-
Authors
Weiss, Joshua M.
Hunter, Miranda V. https://orcid.org/0000-0002-6971-1738
Cruz, Nelly M. https://orcid.org/0000-0002-9040-6957
Baggiolini, Arianna https://orcid.org/0000-0002-2476-561X
Tagore, Mohita https://orcid.org/0000-0002-2586-1427
Ma, Yilun
Misale, Sandra
Marasco, Michelangelo
Simon-Vermot, Theresa
Campbell, Nathaniel R. https://orcid.org/0000-0002-0355-0708
Newell, Felicity https://orcid.org/0000-0003-0469-2705
Wilmott, James S.
Johansson, Peter A.
Thompson, John F. https://orcid.org/0000-0002-2816-2496
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
Pearson, John V.
Mann, Graham J.
Scolyer, Richard A.
Waddell, Nicola https://orcid.org/0000-0002-3950-2476
Montal, Emily D.
Huang, Ting-Hsiang
Jonsson, Philip https://orcid.org/0000-0002-1537-0624
Donoghue, Mark T. A.
Harris, Christopher C.
Taylor, Barry S.
Xu, Tianhao
Chaligné, Ronan https://orcid.org/0000-0003-4332-3291
Shliaha, Pavel V.
Hendrickson, Ronald
Jungbluth, Achim A.
Lezcano, Cecilia
Koche, Richard https://orcid.org/0000-0002-6820-5083
Studer, Lorenz https://orcid.org/0000-0003-0741-7987
Ariyan, Charlotte E.
Solit, David B. https://orcid.org/0000-0002-6614-802X
Wolchok, Jedd D. https://orcid.org/0000-0001-6718-2222
Merghoub, Taha https://orcid.org/0000-0002-1518-5111
Rosen, Neal https://orcid.org/0000-0002-8307-654X
Hayward, Nicholas K.
White, Richard M. https://orcid.org/0000-0001-9099-9169
- License Information
-
More Information
Article History
Received: 14 November 2020
Accepted: 25 February 2022
First Online: 30 March 2022
Competing interests
: S.M. consulted for Boehringer-Ingelheim. J.F.T. has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus, and travel support from GSK and Provectus. R.A.S. has received fees for professional services from Qbiotics, Novartis, MSD Sharp & Dohme, NeraCare, AMGEN, Bristol-Myers Squibb, Myriad Genetics and GlaxoSmithKline. G.V.L. is consultant advisor for Aduro Biotech, Amgen, Array Biopharma, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evaxion Biotech A/S, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals, SkylineDX B.V. and Specialised Therapeutics Australia. J.V.P. and N.W. are equity holders and board members of genomiQa. P.J. is currently employed by Celsius Therapeutics. B.S.T. reports receiving Honoria and research funding from Genentech and Illumina and advisory board activities for Boehringer Ingelheim and Loxo Oncology, a wholly owned subsidiary of Eli Lilly. B.S.T. is currently employed by Loxo Oncology. L.S. is co-founder and consultant of BlueRock Therapeutics. D.B.S. has consulted with/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Vivideon Therapeutics, Q.E.D. Therapeutics and Illumina. J.D.W. is a consultant for Amgen, Apricity, Arsenal, Ascentage Pharma, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F Star, Georgiamune, Imvaq, Kyowa Hakko Kirin, Merck, Neon Therapeutics, Polynoma, Psioxus, Recepta, Trieza, Truvax and Sellas. J.D.W. has grant and research support from Bristol Meyers Squibb and Sephora. J.D.W. has equity in Tizona Pharmaceuticals, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO and Georgiamune. T.M. is a consultant for Leap Therapeutics, Immunos Therapeutics and Pfizer, and co-founder of Imvaq therapeutics. T.M. has equity in Imvaq therapeutics. T.M. reports grants from Bristol Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea. T.M. is inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. N.R. is on the scientific advisory board and receives research funding from Chugai, is on the scientific advisory board and owns equity in Beigene and Fortress. N.R. is also on the scientific advisory board of Daiichi-Sankyo, Astra-Zeneca-MedImmune and F-Prime, and is a past scientific advisory board member of Millenium-Takeda, Kadmon, Kura and Araxes. N.R. is a consultant to Novartis, Boehringer Ingelheim, Tarveda and Foresight and consulted in the last three years with Eli Lilly, Merrimack, Kura Oncology, Araxes and Kadman. N.R. owns equity in ZaiLab, Kura Oncology, Araxes and Kadman. N.R. also collaborates with Plexxikon. R.M.W. is a paid consultant to N-of-One Therapeutics, a subsidiary of Qiagen. R.M.W. receives royalty payments for the use of the casper line from Carolina Biologicals.
